A global standard bearer in basic and applied research to vanquish cancer
IRIC, located in the heart of the Université de Montréal campus, operates according to a unique model in Canada that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team. These generate discoveries that advance knowledge or that can quickly translate into new therapeutic solutions.
IRIC is proud to announce the appointment of Mr. Richard Martin, Director of Administration of the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal since 2011, to the position of Assistant General Director – Operations and Finance.
A few weeks ago, Dr. Robert Patenaude, who has been a chronic myeloid leukemia survivor for almost 40 years thanks to the great care and determination of Dr. Claude Perreault, announced the creation of the brand new Fonds vaccin thérapeutique contre le cancer, along with his generous $25,000 donation. The fund is intended to support the investigators involved in the project, namely the team led by Dr. Claude Perreault, in collaboration with the teams led by Sébastien Lemieux and Pierre Thibault, who work tirelessly and with conviction to change the life of people affected by cancer.
A collaboration between European investigators and the team led by Philippe Roux of IRIC resulted in discovering the unsuspected role of vimentin intermediate filaments in cell division. That discovery is now the subject of an article in the prestigious scientific journal Developmental Cell.
As we begin 2020, IRIC is very proud to announce that the project from the team headed by Dr. Claude Perreault, aimed at developing a therapeutic cancer vaccine, has been nominated as one of the 10 most impressive Quebec discoveries of the past year, a list put forward by Québec Science. The project was carried out in collaboration with the teams headed by Sébastien Lemieux and Pierre Thibault, who are also Principal Investigators at IRIC.
The team led by Katherine L.B. Borden of IRIC, and spearheaded by Drs. Coutinho, Volpon, Culjkovic-Kraljacic and Osborne, accomplished nothing short of discovering a new mode of regulation and possibly production of proteins in cells. Curiously, this finding resulted from a protein structure from a virus that attacks, of all things, potatoes! Investigators unveiled their story in an article published in Proceedings of the National Academy of Sciences of the United States of America (P.N.A.S.).
CQDM is proud to announce that the project led by Michel Bouvier from the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and the biotech Domain Therapeutics was awarded the RSRI Recognition Award during the ADRIQ Innovation Prize Gala held on November 21st.
IRIC is proud that it can count on the tremendous support of Mrs. Rita Baumgartner and Mr. Aldo Baumgartner, who recently announced a $100,000 donation specifically earmarked for fellowships.
On this National Philanthropy Day, IRIC salutes the exceptional commitment made by its Chief Executive Officer, Prof. Michel Bouvier, and his partner, Prof. Muriel Aubry, by announcing their testamentary donation in support of the Université de Montréal and the Institute for Research in Immunology and Cancer (IRIC).
In a Phase One-Two clinical trial, the great majority of patients with blood cancers are on the road to recovery, thanks to the UM171 molecule, discovered at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal.
Hill S, Reichermeier K, Scott DC, Samentar L, Coulombe-Huntington J, Izzi L, Tang X, Ibarra R, Bertomeu T, Moradian A, Sweredoski MJ, Caberoy N, Schulman BA, Sicheri F, Tyers M, Kleiger G
Elife
2019-12-23
;8:.
